The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.f

Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

Publications

Wu S, Liu K, Ren F, Zheng D, Pan D

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report.

BMC pulmonary medicine 2018 Jul 20;18;121 — 2018 Jul 20 — 121

Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jan 01;31;e15-7 — 2013 Jan 01 — e15-7